Does Amerigroup Cover Adderall?

How Amerigroup Formularies Handle Adderall and Generic Equivalents

Amerigroup, a subsidiary of Elevance Health (formerly Anthem), operates Medicaid managed care and Medicare Advantage plans across more than 20 states. Each state contract produces a distinct preferred drug list (PDL), so the answer to "does Amerigroup cover Adderall" depends on which plan you hold and where you live.

On most Amerigroup Medicaid formularies, generic mixed amphetamine salts (the bioequivalent of Adderall IR) sit at a preferred generic tier with $0 to $3 copays. The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) rates these generics as "AB-rated," meaning the agency considers them interchangeable with brand Adderall. Brand-name Adderall IR, manufactured by Teva, is frequently excluded or placed on a non-preferred tier because the generic alternative is widely available and costs a fraction of the brand price.

Adderall XR (extended-release) presents a different picture. Several Amerigroup state plans list generic extended-release mixed amphetamine salts at a preferred tier but require prior authorization for the brand-name XR capsule. A 2023 analysis published in JAMA Network Open found that among Medicaid managed care organizations nationally, 78% imposed at least one utilization management restriction on brand-name extended-release stimulants [1]. Amerigroup follows this pattern closely. Step therapy protocols often require a trial of immediate-release generic amphetamine or methylphenidate before the plan approves an extended-release formulation, a sequence consistent with the American Academy of Pediatrics (AAP) ADHD clinical practice guideline recommending FDA-approved medications as first-line therapy for ADHD in children aged 6 and older [2].

Prior Authorization Requirements for Adderall on Amerigroup Plans

Prior authorization (PA) is the most common barrier members encounter when filling an Adderall prescription through Amerigroup. PA requirements exist to verify medical necessity and confirm that cheaper or clinically equivalent alternatives have been tried.

For generic immediate-release mixed amphetamine salts, many Amerigroup Medicaid formularies do not require PA at all. The prescription can be filled at any in-network pharmacy with no additional paperwork. Brand-name Adderall IR, by contrast, almost always triggers a PA flag because generic equivalents are available.

For Adderall XR (brand or generic extended-release), Amerigroup plans in states like Texas, Georgia, and Florida commonly require a PA demonstrating that the patient has tried and failed (or has a contraindication to) immediate-release stimulant therapy. The Centers for Medicare & Medicaid Services (CMS) mandates that Medicaid managed care plans process non-urgent PA requests within 72 hours and provide a 72-hour emergency supply of a covered drug while the authorization is pending [3]. This federal floor applies to all Amerigroup Medicaid contracts.

Your prescriber submits the PA, usually by completing a form through Amerigroup's pharmacy benefits portal or by fax. The form typically asks for the diagnosis (ICD-10 code F90.0 through F90.9 for ADHD), prior medication trials, dosage, and duration of therapy requested. A retrospective cohort study in Pediatrics (N=1,799) found that PA requirements for ADHD stimulants delayed initial medication fills by a mean of 7.2 days, a clinically meaningful gap for patients with moderate-to-severe symptoms [4]. The AAP recommends initiating ADHD pharmacotherapy promptly once the diagnosis is confirmed, particularly in school-age children where academic impairment can compound quickly [2].

For Medicare Advantage members enrolled in an Amerigroup plan, CMS Part D formulary rules apply instead. Under Part D, mixed amphetamine salts are typically listed on Tier 2 (generic) with copays ranging from $5 to $20, while brand Adderall XR may sit on Tier 3 or Tier 4, carrying copays of $35 to $47 depending on the plan year [5].

Step Therapy Protocols: What You Must Try First

Step therapy, sometimes called "fail first," requires that a patient try one or more preferred medications before the plan covers a non-preferred drug. Amerigroup applies step therapy to Adderall XR and brand Adderall in several state Medicaid contracts.

The typical Amerigroup step therapy sequence for extended-release stimulants starts with generic methylphenidate (Ritalin equivalent) or generic immediate-release mixed amphetamine salts. If the patient does not respond adequately, experiences intolerable side effects, or has a documented contraindication, the prescriber can request an override. The Endocrine Society's clinical practice guidelines and the AAP both acknowledge that stimulant response is highly individual. A meta-analysis in The Lancet Psychiatry (N=10,068 children and adolescents across 133 trials) found that methylphenidate and amphetamine had comparable overall efficacy but that individual response rates varied by approximately 30%, meaning a substantial minority of patients respond to one class but not the other [6].

This variability is why step-therapy overrides exist. If your child or adolescent has been stable on Adderall XR through a previous insurer, Amerigroup plans generally accept documentation of that prior stable therapy as grounds for a step-therapy exception. The key is providing pharmacy claims or medical records showing a minimum 30-day history on the requested medication. A study published in Health Affairs found that among Medicaid beneficiaries required to go through step therapy for ADHD stimulants, 42% received an exception within two weeks when the prescriber submitted clinical documentation [7].

Under federal law, the Mental Health Parity and Addiction Equity Act (MHPAEA) requires that non-quantitative treatment limitations (including step therapy) for mental health conditions be no more restrictive than those applied to medical/surgical conditions [8]. If you believe Amerigroup's step-therapy protocol is more burdensome for ADHD than for a comparable medical condition, you may have grounds for a parity complaint through your state insurance regulator or CMS.

Generic vs. Brand Adderall: Cost and Coverage Differences on Amerigroup

The price gap between generic and brand Adderall is wide. According to the FDA's National Drug Code Directory, more than a dozen manufacturers produce AB-rated generic mixed amphetamine salts in both IR and XR formulations. Wholesale acquisition cost for a 30-day supply of generic mixed amphetamine salts 20 mg IR runs approximately $25 to $45, while brand Adderall IR (when available) costs over $300 [9].

For Amerigroup Medicaid members, generic IR copays range from $0 in states that prohibit Medicaid copays for children (as outlined in the Social Security Act Section 1916) to $3 for adult beneficiaries. Generic XR copays typically fall between $1 and $10. Brand-name XR, if approved through PA, may carry a specialty-tier copay of $15 to $50 or require a formulary exception for preferred-tier pricing.

Medicare Advantage members face a different structure. Under CMS Part D guidelines, mixed amphetamine salts are classified as a Part D drug, not a Part B drug, so coverage runs through the plan's pharmacy benefit. The 2025 CMS Part D redesign introduced a $2,000 annual out-of-pocket cap that applies to all covered prescriptions, including stimulants, effectively limiting the total yearly cost burden for Adderall and similar medications [10].

A point worth highlighting: some Amerigroup plans in states with 340B contract pharmacies may offer $0 copays on generic stimulants for qualifying low-income members regardless of tier placement. Check with your plan's pharmacy help line to see if 340B pricing applies to your prescription.

How to Check Your Specific Amerigroup Formulary

Because Amerigroup operates under different state Medicaid and Medicare Advantage contracts, the only reliable way to confirm Adderall coverage is to check your plan's current formulary.

The fastest method: log in to the Amerigroup member portal for your state plan and search the drug formulary tool for "amphetamine" or "mixed amphetamine salts." The result will show the tier, PA requirement, quantity limit, and any step-therapy flag. Alternatively, call the member services number on the back of your Amerigroup card. Request a "pharmacy benefit inquiry" and specify the drug name, strength, and NDC number if available.

Prescribers can verify coverage in real time through electronic prior authorization (ePA) platforms. A 2022 study in the Journal of the American Medical Association found that ePA reduced PA processing time by 60% compared to fax-based workflows, cutting average approval time from 4.8 days to 1.9 days [11]. Ask your prescriber's office whether they use ePA with Amerigroup's pharmacy benefit manager.

The American Academy of Family Physicians (AAFP) recommends that clinicians confirm insurance formulary status before writing stimulant prescriptions to avoid fill delays, a practical step that prevents the week-long gaps documented in the Pediatrics cohort study referenced earlier [4]. For patients switching to Amerigroup from another plan, bring your current prescription bottle, pharmacy records, and any prior authorization approval letter to your first appointment so the new prescriber can expedite the PA process.

Quantity Limits and Refill Rules for Adderall Under Amerigroup

Amerigroup imposes quantity limits on Schedule II controlled substances, including all amphetamine formulations. Limits vary by state, but common parameters include 30 tablets per 30 days for Adderall IR (at standard twice-daily dosing) and 30 capsules per 30 days for Adderall XR (once-daily dosing).

Some state contracts allow up to 60 tablets per 30-day fill for IR formulations when the prescriber documents three-times-daily dosing, though this is less common for ADHD (more typical in narcolepsy). Under DEA Schedule II prescribing rules, prescribers may write up to 90 days of prescriptions at once (three separate 30-day scripts with "do not fill until" dates), a protocol Amerigroup honors in most states [12].

Early refill rules typically prevent a fill more than 2 to 3 days before the calculated run-out date. A 2021 analysis in Drug and Alcohol Dependence found that early refill restrictions on Schedule II stimulants reduced stimulant diversion indicators by 22% in Medicaid populations without increasing emergency department visits for ADHD-related crises [13]. These limits protect patients and the broader community while preserving access for those who use the medications as prescribed.

What to Do If Amerigroup Denies Adderall Coverage

A denial is not the end of the road. Amerigroup members have the right to appeal any pharmacy coverage denial through a multi-step process.

Step 1: Request a formulary exception. Your prescriber writes a letter of medical necessity explaining why the denied medication is clinically required. The letter should reference specific diagnostic criteria from the DSM-5 (Diagnostic and Statistical Manual) and document prior medication trials, doses, durations, and reasons for failure [14].

Step 2: Internal appeal. If the formulary exception is denied, you (or your prescriber) can file a formal internal appeal. Amerigroup must decide Medicaid appeals within 30 days for standard requests or 72 hours for expedited requests involving imminent health risk, per CMS Medicaid managed care regulations at 42 CFR 438.408.

Step 3: External review. If the internal appeal is denied, Medicaid members can request a state fair hearing. Medicare Advantage members can escalate to an Independent Review Entity (IRE) through the CMS Part D appeals process [15].

A study published in the Annals of Internal Medicine found that among Medicaid managed care denials that were formally appealed, 48% were overturned at the internal appeal stage, and an additional 19% were overturned at external review [16]. The success rates are higher when the appeal includes supporting evidence from clinical guidelines. "Coverage denial does not equate to lack of medical necessity," the AAFP's prior authorization reform policy states. "Patients and physicians should not accept an initial denial as a final answer" [17].

ADHD Medication Alternatives Covered by Amerigroup

If the PA or appeal process is too time-consuming, or if your prescriber believes a different medication may work as well, several ADHD pharmacotherapies sit on Amerigroup formularies without PA in most states.

Generic methylphenidate IR (5, 10, 20 mg) is the most universally covered ADHD stimulant on Amerigroup plans. The National Institute of Mental Health (NIMH) lists both methylphenidate and amphetamine as first-line stimulant classes for ADHD treatment. The landmark MTA Cooperative Group trial (N=579) demonstrated that methylphenidate-based medication management was superior to behavioral therapy alone and to community care at 14 months for core ADHD symptoms [18].

Generic methylphenidate ER (Concerta equivalents) is also preferred on many Amerigroup PDLs. Atomoxetine (generic Strattera), a non-stimulant, is typically covered at a generic tier, though it carries the limitation of slower onset (4 to 6 weeks for full effect) compared to stimulants. Guanfacine ER (generic Intuniv) is another non-stimulant option often available without PA, recommended as monotherapy or adjunctive therapy in the AAP ADHD guideline for children aged 6 to 17 [2].

Lisdexamfetamine (Vyvanse) became available as a generic in 2023 after patent expiration. Generic lisdexamfetamine is appearing on Amerigroup formularies in an increasing number of states, though some plans still require PA. Because lisdexamfetamine is a prodrug activated only in the GI tract, it has a lower abuse potential than immediate-release amphetamine, a finding supported by a randomized human abuse liability study published in the Journal of Clinical Psychopharmacology (N=38 stimulant abusers) [19].